---
title: "Stifel Nicolaus Keeps Their Buy Rating on DRI Healthcare (DHT.UN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285420241.md"
description: "Stifel Nicolaus analyst Justin Keywood has maintained a Buy rating on DRI Healthcare (DHT.UN) with a price target of C$22.00. The analyst focuses on the Healthcare sector and has an average return of -1.5% with a 50.94% success rate on stock recommendations. The current analyst consensus for DRI Healthcare is a Moderate Buy, with an average price target of C$21.50."
datetime: "2026-05-06T18:15:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285420241.md)
  - [en](https://longbridge.com/en/news/285420241.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285420241.md)
generator: "portal-rs"
---

# Stifel Nicolaus Keeps Their Buy Rating on DRI Healthcare (DHT.UN)

Stifel Nicolaus analyst Justin Keywood maintained a Buy rating on DRI Healthcare today and set a price target of C$22.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Keywood covers the Healthcare sector, focusing on stocks such as WELL Health Technologies Corp, NervGen Pharma, and DRI Healthcare. According to TipRanks, Keywood has an average return of -1.5% and a 50.94% success rate on recommended stocks. 

Currently, the analyst consensus on DRI Healthcare is a Moderate Buy with an average price target of C$21.50.

### Related Stocks

- [DRIO.US](https://longbridge.com/en/quote/DRIO.US.md)
- [PHLT.US](https://longbridge.com/en/quote/PHLT.US.md)
- [SRTS.US](https://longbridge.com/en/quote/SRTS.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [XHS.US](https://longbridge.com/en/quote/XHS.US.md)
- [IHF.US](https://longbridge.com/en/quote/IHF.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [NGEN.US](https://longbridge.com/en/quote/NGEN.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Sensus Healthcare director Eric Sachetta acquires 31,000 common shares valued at $98,258](https://longbridge.com/en/news/296821898.md)
- [Analyst Sees Operational Inflection and Strengthening Demand Supporting Buy Rating on Sensus Healthcare](https://longbridge.com/en/news/296006310.md)
- [Corby Spirit and Wine boosts dividend by 4.2% to CAD 0.25 a share](https://longbridge.com/en/news/297124377.md)
- [Mercer International secures C$20M Canadian Government support; shares surge](https://longbridge.com/en/news/297089583.md)
- [BioSyent GAAP EPS of C$0.25, revenue of C$19.87M](https://longbridge.com/en/news/296538491.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**